Unicycive Therapeutics Inc (UNCY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Unicycive Therapeutics Inc (UNCY) has a cash flow conversion efficiency ratio of -0.266x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.03 Million) by net assets ($30.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See UNCY defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Unicycive Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Unicycive Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Unicycive Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Unicycive Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gulf Island Fabrication Inc
NASDAQ:GIFI
|
0.030x |
|
Finwise Bancorp
NASDAQ:FINW
|
0.018x |
|
Arman Financial Services Limited
NSE:ARMANFIN
|
0.093x |
|
Catella AB (publ)
ST:CAT-B
|
0.009x |
|
SOL-GEL TECHN. IS-10
F:4SG
|
N/A |
|
CVW CleanTech Inc
V:CVW
|
-0.006x |
|
GTM Holdings Corp
TW:1437
|
0.010x |
|
Hoegh LNG Partners LP
OL:HLNG
|
0.109x |
Annual Cash Flow Conversion Efficiency for Unicycive Therapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Unicycive Therapeutics Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Unicycive Therapeutics Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $30.20 Million | $-31.32 Million | -1.037x | +73.03% |
| 2024-12-31 | $7.43 Million | $-28.57 Million | -3.845x | -180.11% |
| 2023-12-31 | $-3.81 Million | $-18.28 Million | 4.800x | -85.71% |
| 2022-12-31 | $-466.00K | $-15.65 Million | 33.586x | +9699.95% |
| 2021-12-31 | $16.48 Million | $-5.77 Million | -0.350x | -164.05% |
| 2020-12-31 | $-2.67 Million | $-1.46 Million | 0.546x | -58.94% |
| 2019-12-31 | $-884.00K | $-1.18 Million | 1.330x | +107.01% |
| 2018-12-31 | $-1.21 Million | $-775.00K | 0.643x | -- |
About Unicycive Therapeutics Inc
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester deriv… Read more